Table 4.
Median (95% CI) | Bevacizumab maintenance arm | Observation maintenance arm | ||||
---|---|---|---|---|---|---|
VEGFR-1 rs9582036 | CC N = 14 | CA + AA N = 146 | p | CC N = 16 | CA + AA N = 138 | p |
TCD | 22.4 (14.8–NR) | 14.4 (11.7–17.1) | 0.047 | NR (9.5–NR) | 15.7 (12.7–21.9) | 0.079 |
OS | 28.2 (18.1–42.8) | 22.5 (18.6–24.6) | 0.510 | 22.66 (17.2–NR) | 22.1 (19.5–25.2) | 0.097 |
PFS | 9.4 (7.2–11.3) | 9.2 (8.71–10.1) | 0.59 | 9.3 (7.5–10.8) | 9.10 (7.9–9.7) | 0.785 |
First CFI (IQR) | 4.6 (3.3–7.4) | 4.14 (2.3–6.1) | 0.303 | 3.15 (2.6–4.9) | 4 (2.7–6.0) | 0.493 |
CFI, chemotherapy-free interval; IQR, interquartile range; OS, overall survival; PFS, progression-free survival; TCD, tumor control duration; VEGFR, vascular endothelial growth factor receptor.